The FDA has granted fast track designation to nadunolimab for use in combination with gemcitabine and nab-paclitaxel to treat patients with previously untreated, metastatic PDAC with high IL1RAP ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

The Clinical Advisor spoke with Carlos Gutiérrez, EdD, MMS, PA-C, about the impact of executive orders on LGBTQ+ health care.

Workers at the NIH sent a letter protesting the Trump administration’s cuts to the agency's budget, staff, and research.

The ACIP is a federal advisory committee composed of medical and public health experts who make recommendations on the use of vaccines for adults and children in the US.

Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Study results highlight the need to improve adverse event cost quantification in oncology cost-effectiveness analyses, researchers say.

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.

Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

Younger cancer survivors were more likely than their older peers to start alcohol use disorder treatment within 1 year of diagnosis. Less than 15% of cancer survivors diagnosed with alcohol use ...